Review
Oncology
Yijing Zhao, Hanfei Guo, Yingjun Chang
Summary: This review summarizes the methods, sample sources, and evaluation frequency of MRD assessment in acute myeloid leukemia (AML) according to the risk category of the European Leukemia Net (ELN) 2022. It emphasizes the importance of properly utilizing and combining these technologies and provides a flowchart outlining each time point for pre-emptive interventions and intervention paths. The evaluation of MRD in AML is complex, clinically applicable, technology-dependent, and requires standardized approaches and further research.
CHINESE JOURNAL OF CANCER RESEARCH
(2023)
Article
Hematology
Huanping Wang, Yile Zhou, Xin Huang, Yi Zhang, Jiejing Qian, Jianhu Li, Chenying Li, Xueying Li, Yinjun Lou, Qiaoyun Zhu, Yujie Huang, Haitao Meng, Wenjuan Yu, Hongyan Tong, Jie Jin, Hong-Hu Zhu
Summary: In adult T-cell acute lymphoblastic leukemia (T-ALL) patients, inductions end-stage MRD based on FCM is an independent prognostic factor for relapse and survival. EOI-MRD positivity can predict post-transplant relapse in patients undergoing allo-HSCT for the first remission.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Oncology
Cornelia Eckert, Catriona Parker, Anthony Moorman, Julie A. E. Irving, Renate Kirschner-Schwabe, Stefanie Groeneveld-Krentz, Tamas Revesz, Peter Hoogerbrugge, Jeremy Hancock, Rosemary Sutton, Guenter Henze, Christiane Chen-Santel, Andishe Attarbaschi, Jean-Pierre Bourquin, Lucie Sramkova, Martin Zimmermann, Shekhar Krishnan, Arend von Stackelberg, Vaskar Saha
Summary: The study analyzed the outcomes of children with high-risk relapsed acute lymphoblastic leukaemia (ALL), and found that a good minimal residual disease (MRD) response was associated with better disease-free survival and overall survival. After hematopoietic stem cell transplantation (SCT), there were differences in the rates of relapse and death between B-cell precursor (BCP) and T-cell ALL.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Hematology
Asiri Ediriwickrema, Andrew J. Gentles, Ravindra Majeti
Summary: The era of genomic medicine has advanced AML research, but AML remains a lethal cancer due to its complex and plastic cellular architecture. Single-cell genomics has the potential to address the challenges posed by cellular heterogeneity and provide unique opportunities in AML research.
Article
Oncology
Johannes Kirsten, Verena Wais, Sebastian V. W. Schulz, Elisa Sala, Gunnar Treff, Donald Bunjes, Jurgen M. Steinacker
Summary: Allogenic stem cell transplantation (aSCT) is a potentially curative treatment for high-risk hematological diseases, but is associated with significant mortality. A new sarcopenia assessment based on muscle mass, grip strength, and aerobic capacity was implemented to predict all-cause and non-relapse mortality in aSCT patients. Patients with sarcopenia showed a three-fold increase in mortality, emphasizing the importance of physical performance status in predicting complications in aSCT.
Article
Multidisciplinary Sciences
Weijie Cao, Xiaoning Li, Ran Zhang, Zhilei Bian, Suping Zhang, Li Li, Haizhou Xing, Changfeng Liu, Xinsheng Xie, Zhongxing Jiang, Xiaosheng Fang, Dingming Wan, Jifeng Yu
Summary: In this study, we aimed to validate and prove the effectiveness of AML-DRG and AML-HCT-CR models in predicting post-transplant survival in patients with acute myeloid leukemia (AML) receiving allogeneic hematopoietic stem cell transplantation (AHCT). Our results showed that these models significantly predicted the cumulative incidence of relapse and AML-DRG model demonstrated better stratification of AML patients into different risk groups compared to the AML-HCT-CR model. Multivariate analysis confirmed the independent prognostic impact of these models on post-transplant overall survival.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Teresa Caballero-Velazquez, Olga Perez-Lopez, Ana Yeguas Bermejo, Eduardo Rodriguez Arboli, Enrique Colado Varela, Amparo Sempere Talens, Maria Belen Vidriales, Maria Sole-Rodriguez, Covadonga Quiros Caso, Estefania Perez Lopez, Marta Reinoso Segura, Concepcion Prats-Martin, Pau Montesinos, Jose A. Perez-Simon
Summary: This study aimed to evaluate the prognostic value of measurable residual disease (MRD) in AML patients undergoing hematopoietic stem cell transplantation (HSCT). MRD detection before and after transplantation has prognostic value, and positive MRD on day +100 after transplantation is associated with a poor prognosis. Standardized MRD testing can predict the outcome of AML patients in real life.
Article
Hematology
Gabrielle Paras, Linde M. Morsink, Megan Othus, Filippo Milano, Brenda M. Sandmaier, Lucas C. Zarling, Raffaele Palmieri, Gary Schoch, Chris Davis, Marie Bleakley, Mary E. D. Flowers, H. Joachim Deeg, Frederick R. Appelbaum, Rainer Storb, Roland B. Walter
Summary: In AML, assessing MRD status before and after allogeneic HCT is crucial for predicting patient outcomes. The dynamics of peri-HCT MRD can significantly impact relapse risk and survival probabilities across varying conditioning intensities, improving risk assessment in AML patients compared to isolated pre- or post-HCT MRD assessments.
Letter
Oncology
Tanzhen Wang, Biqi Zhou, Jubin Zhang, Xinyue Zhang, Tianhui Liu, Huiying Qiu, Aining Sun, Suning Chen, Depei Wu, Yang Xu
Summary: The study found that MRD positivity after two consolidation courses significantly affects overall survival, progression-free survival, and cumulative incidence of relapse in patients with favorable-risk CBF-AML in first complete remission. Moreover, the MRD status after two consolidation courses may be the optimal timing for treatment choice, and allo-HSCT is a promising option for favorable-risk CBF-AML patients who are MRD positive after the second consolidation.
LEUKEMIA & LYMPHOMA
(2021)
Article
Medicine, General & Internal
Le-Qing Cao, Yang Zhou, Yan-Rong Liu, Lan-Ping Xu, Xiao-Hui Zhang, Yu Wang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei Han, Yu-Qian Sun, Chen-Hua Yan, Fei-Fei Tang, Xiao-Dong Mo, Kai-Yan Liu, Qiao-Zhen Fan, Ying-Jun Chang, Xiao-Jun Huang
Summary: The study aimed to establish a risk score system for predicting transplant outcomes in B-ALL patients after allo-SCT. Factors associated with transplant outcomes were evaluated, and a risk score based on certain variables was formulated to predict relapse rates. The study found that patients with positive post-transplantation minimal residual disease, transplanted beyond the first complete remission, and without chronic graft-versus-host disease had higher relapse rates and worse survival outcomes.
CHINESE MEDICAL JOURNAL
(2021)
Review
Immunology
Guancui Yang, Xiang Wang, Shiqin Huang, Ruihao Huang, Jin Wei, Xiaoqi Wang, Xi Zhang
Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for myeloid malignancies, but relapse and graft-versus-host disease (GvHD) still impact patient survival. Epigenetic agents, such as hypomethylating agents (HMAs), have been explored to reduce relapse risk and prevent GvHD, and combining epigenetic therapy with HSCT may optimize the transplantation process and prevent treatment failure.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Jun Kong, Meng-Ge Gao, Ya-Zhen Qin, Yu Wang, Chen-Hua Yan, Yu-Qian Sun, Ying-Jun Chang, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Su Zhao
Summary: This study aimed to analyze the dynamic changes of MLL-PTD peri-transplantation and determine the best threshold for predicting relapse after transplantation. The study included 48 patients with MLL-PTD AML or MDS-EB who underwent allo-HSCT. The results showed that MLL-PTD after transplantation can serve as an effective indicator for predicting relapse. The expression level of MLL-PTD >= 1.0% was identified as the optimal cut-off value for predicting hematological relapse after allo-HSCT.
Article
Oncology
Shan Chong, Yun He, Yejun Wu, Peng Zhao, Xiaolu Zhu, Fengrong Wang, Yuanyuan Zhang, Xiaodong Mo, Wei Han, Jingzhi Wang, Yu Wang, Huan Chen, Yuhong Chen, Xiangyu Zhao, Yingjun Chang, Lanping Xu, Kaiyan Liu, Xiaojun Huang, Xiaohui Zhang
Summary: In patients who developed skin and soft tissue infections (SSTIs) after hematopoietic stem cell transplantation (HSCT), primary platelet graft failure (PPGF), comorbidities of acute kidney injury (AKI), and hospital-acquired pneumonia (HAP) were identified as independent risk factors for death. A risk stratification system was established, which showed good accuracy in predicting mortality risk.
FRONTIERS OF MEDICINE
(2022)
Article
Medicine, General & Internal
Yongzhan Zhang, Lu Bai, Yifei Cheng, Aidong Lu, Yu Wang, Jun Wu, Xiaohui Zhang, Yingxi Zuo, Lanping Xu, Yueping Jia, Xiaojun Huang, Leping Zhang
Summary: This study found that allo-HSCT, especially haplo-HSCT, can improve survival and reduce relapse in high-risk T-ALL children. Minimal residual disease re-emergence, age, and high white blood cell count are independent risk factors that affect prognosis.
CHINESE MEDICAL JOURNAL
(2022)
Editorial Material
Hematology
Sena Kim, Jaebok Choi
Summary: This study demonstrates that the activation of TGF-beta 1 by Tregs through GARP downregulates the effector functions of NK cells in the bone marrow of AML patients with early relapse after allo-HCT, and that blocking TGF-beta 1 signaling can restore the killer instinct of human NK cells.